Avacopan Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 10 mg
Reference Brands: Tavneos (USA/EU)
Category:
Immune Disorder
Avacopan is available in Capsules
and strengths such as 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Avacopan is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Avacopan can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Avacopan is a targeted immunomodulatory medicine sold under the brand name Tavneos and is used in the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. This includes serious autoimmune conditions such as granulomatosis with polyangiitis and microscopic polyangiitis. It is prescribed for adults with severe active disease and is used together with standard background therapy, including glucocorticoids and other immunosuppressive agents.
Avacopan works as a selective complement 5a (C5a) receptor antagonist. By blocking the C5a receptor on neutrophils, it reduces complement-driven inflammation and prevents excessive activation and migration of these immune cells to blood vessel walls. This helps limit vascular inflammation and tissue damage associated with ANCA-associated vasculitis. In addition to its primary mechanism, avacopan also acts as a cytochrome P450 3A4 inhibitor, which is an important consideration for potential drug interactions.
Through its targeted pathway, avacopan provides a steroid-sparing treatment approach and represents an important advancement in the management of severe ANCA-associated vasculitis.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing